From: Gross, Mary Sent: Friday, August 09, 2002 3:39 PM To: Butler, Jennie C Subject: FW: Bar Code Public Meeting -----Original Message----- From: Craig Weingarten, Big Fish [mailto:cweingarten@beabigfish.com] Sent: Friday, July 12, 2002 5:18 PM To: grossm@cder.fda.gov Subject: Bar Code Public Meeting Below is a short summary of the presentation Stephen Polinsky of GenuOne, Inc. would like to give at the Bar Code Label Requirements for Human Drug Products Public Meeting on July 26. I understand you are out of the office today, so I will contact you on Monday, July 15, to confirm your receipt of this email. Best regards, Craig S. Weingarten Director of Public Relations and Planning Big Fish Communications www.BeaBigFish.com cweingarten@beabigfish.com W: 617.713.0252 Authentication and Tracking of Medical Devices, Human Drug and Biologic Products Stephen Polinsky GenuOne In May 2001, investigators from Columbia’s National Institute for the Supervision of Medications and Food discovered a thriving drug business in Bogotá. What they originally thought was a cocaine or heroin factory instead turned out to be a factory producing the flu drug Dristan and Ponstan 500, a painkiller made by Pfizer. The Columbian official in charge of the investigation said the pills contained boric acid, cement, floor wax, talcum powder and yellow paint with high levels of lead, all in an effort to replicate the drugs genuine appearance. This is not an isolated incident. Medical product manufacturers and pharmaceutical companies spend millions of dollars per year to create some of the world’s most sophisticated products and drugs; yet often the quality and integrity of packaging is overlooked. Companies are feeling the financial and social pressures to raise the sophistication of their packaging and coding to ensure consumer confidence and safety, while mitigating industry risks of product liability and negligence. New regulations require a lot of effort to be born, therefore the FDA should ensure, if they are creating guidelines for bar-coding, that they consider all product tagging and tracking implications.